

Respiratory Syncytial Virus Vaccines Market Size, Share and Growth Outlook 2026: By Product Type, By Immunization Approach, By Technology Platform, By Route of Administration, By End User, Companies to 2034

<https://marketpublishers.com/r/RF4926DCD11EEN.html>

Date: July 2026

Pages: 190

Price: US\$ 3,482.00 (Single User License)

ID: RF4926DCD11EEN

Abstracts

The global Respiratory Syncytial Virus Vaccines Market size is forecast to increase from \$4.05 Billion in 2026 to \$5.65 Billion in 2034 at a CAGR of 4.26% between 2026 and 2034.

The Respiratory Syncytial Virus Vaccines market report provides detailed analysis and outlook of Respiratory Syncytial Virus Vaccines segments including By Product Type (Elderly RSV Vaccines, Pediatric RSV Vaccines, Maternal RSV Vaccines), By Immunization Approach (Active Immunization, Passive Immunization), By Technology Platform (Recombinant / Subunit Protein-based Vaccines, mRNA-based Vaccines, Viral Vector-based Vaccines, Live Attenuated Vaccines), By Route of Administration (Intramuscular Injection, Intranasal / Mucosal Delivery), By End User (Hospitals and Specialized Clinics, Retail Pharmacies and Drugstores, Government Procurement / Public Health Vaccination Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Respiratory Syncytial Virus (RSV) Vaccines Industry Overview

Expanded Immunization Programs, Manufacturing Scale-Up, and Broader Adult Protection Are Transforming the RSV Prevention Market

The respiratory syncytial virus (RSV) vaccines industry is entering a new phase of

commercialization characterized by expanded immunization recommendations, increasing manufacturing investments, and broader protection strategies across both pediatric and adult populations. Once primarily associated with infant disease, RSV is now recognized as a major cause of severe lower respiratory tract infections among older adults and individuals with chronic medical conditions, driving substantial investments in vaccines and long-acting preventive therapies. Governments and healthcare systems are increasingly incorporating RSV prevention into national immunization frameworks, while manufacturers are rapidly expanding production capabilities to support anticipated seasonal demand and wider population coverage.

Regulatory Expansion and Public Health Policies Accelerate Vaccine Adoption

A major trend shaping the market is the broadening of eligible patient populations through regulatory approvals and national vaccination programs. Reflecting this shift, Moderna, Inc. received expanded U.S. regulatory approval for its mRNA-based RSV vaccine, mResvia, extending its use beyond adults aged 60 years and older to include high-risk adults aged 18 to 59 with underlying medical conditions. Similarly, public health authorities are widening access to RSV immunization among older adults. The UK's national immunization program, guided by the Joint Committee on Vaccination and Immunisation and the Department of Health and Social Care, lowered the routine vaccination age threshold and expanded eligibility to long-term care residents, continuing to recommend Abrysvo from Pfizer as the preferred vaccine option. These policy changes are significantly increasing the addressable market for RSV preventive products.

Manufacturing Expansion and Long-Acting Prevention Strategies Strengthen Market Readiness

The RSV prevention landscape is also being reshaped by substantial investments in manufacturing capacity and long-duration protective therapies. Sanofi, together with its manufacturing partner AstraZeneca, significantly expanded production capabilities for the long-acting monoclonal antibody Beyfortus by tripling global manufacturing capacity and doubling production sites. The European label update extending documented protection to six months further strengthens the value proposition of long-acting passive immunization strategies. These developments underscore the industry's transition toward comprehensive RSV prevention ecosystems that combine vaccines and monoclonal antibodies to protect diverse patient populations throughout seasonal outbreaks.

Respiratory Syncytial Virus Vaccines Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Respiratory Syncytial Virus Vaccines market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GSK plc, Pfizer Inc., Moderna, Inc., Sanofi S.A., AstraZeneca plc, Merck & Co., Inc., Bavarian Nordic, Icosavax, Inc., Meissa Vaccines, Inc., Codagenix, Inc.. The Respiratory Syncytial Virus Vaccines market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Respiratory Syncytial Virus Vaccines industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.

The report provides detailed market analysis including-

- Growth Respiratory Syncytial Virus Vaccines Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Respiratory Syncytial Virus Vaccines companies

- Porter's Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

- Detailed SWOT Analysis of global and regional Respiratory Syncytial Virus Vaccines markets

- Competitive analysis including business description, product analysis, and financial profiles

- Key country specific analysis detailing key factors shaping the short-term and long-term outlook

- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Respiratory Syncytial Virus Vaccines Market Competitive Benchmarking and Company Analysis

Leading companies in Respiratory Syncytial Virus Vaccines industry include- GSK plc, Pfizer Inc., Moderna, Inc., Sanofi S.A., AstraZeneca plc, Merck & Co., Inc., Bavarian Nordic, Icosavax, Inc., Meissa Vaccines, Inc., Codagenix, Inc.. The Respiratory Syncytial Virus Vaccines market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Respiratory Syncytial Virus Vaccines Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach \$8.2 Trillion in 2034 from \$5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Respiratory Syncytial Virus Vaccines market remains one of the strongest-performing segments in the country.

The US Respiratory Syncytial Virus Vaccines Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Respiratory Syncytial Virus Vaccines market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Respiratory Syncytial Virus Vaccines industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Respiratory Syncytial Virus Vaccines markets

Canada's strong Respiratory Syncytial Virus Vaccines sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Respiratory Syncytial Virus Vaccines market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada's largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Respiratory Syncytial Virus Vaccines Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Respiratory Syncytial Virus Vaccines market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Respiratory Syncytial Virus Vaccines population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Respiratory Syncytial Virus Vaccines industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Respiratory Syncytial Virus Vaccines market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Respiratory Syncytial Virus Vaccines sales through 2034

France Respiratory Syncytial Virus Vaccines companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country's National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country's healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to

improve system efficiency drive the long-term prospects.

The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France's market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Respiratory Syncytial Virus Vaccines Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Respiratory Syncytial Virus Vaccines distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England's plan to give more than 500,000 staff access to new AI tools.

China Respiratory Syncytial Virus Vaccines Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Respiratory Syncytial Virus Vaccines market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Respiratory Syncytial Virus Vaccines industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.

The National Healthcare Security Administration reported that by end-2024, China's basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more

pronounced in the Chinese Respiratory Syncytial Virus Vaccines industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Respiratory Syncytial Virus Vaccines Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Respiratory Syncytial Virus Vaccines market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Respiratory Syncytial Virus Vaccines market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Respiratory Syncytial Virus Vaccines Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria,

and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Respiratory Syncytial Virus Vaccines Market Segmentation

By Product Type

Elderly RSV Vaccines

Pediatric RSV Vaccines

Maternal RSV Vaccines

By Immunization Approach

Active Immunization

Passive Immunization

By Technology Platform

Recombinant / Subunit Protein-based Vaccines

mRNA-based Vaccines

Viral Vector-based Vaccines

Live Attenuated Vaccines

By Route of Administration

Intramuscular Injection

Intranasal / Mucosal Delivery

By End User

Hospitals and Specialized Clinics

Retail Pharmacies and Drugstores

Government Procurement / Public Health Vaccination Centers

Leading Companies in Respiratory Syncytial Virus Vaccines Industry (2026)

GSK plc

Pfizer Inc.

Moderna, Inc.

Sanofi S.A.

AstraZeneca plc

Merck & Co., Inc.

Bavarian Nordic

Icosavax, Inc.

Meissa Vaccines, Inc.

Codagenix, Inc.

Countries Included

North America- US, Canada, Mexico

Europe- Germany, France, UK, Spain, Italy, Nordics, Others

Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia,
Others

Latin America- Brazil, Argentina, Others

Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa,
Other Africa

Key Benefits of Procuring the Analysis

Get Free print authentication across single, multi, and global licenses

Free Accompanying excel spreadsheet with complete quantitative data

Free 2-day consulting support from the lead analyst of the team that developed the report

Strategic Value of the Electrosurgical Generators Market Analysis

Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly

Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry

Stay ahead of competition through a detailed analysis of recent market developments

Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry

Contents

CHAPTER 1- EXECUTIVE SUMMARY

- 1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
- 1.2. Key Industry Highlights, 2026
- 1.3. Premium Market Insights
 - 1.3.1. Potential Respiratory Syncytial Virus Vaccines Market Types and Applications
 - 1.3.2. Fastest Growing Countries Over the forecast period
- 1.4. Market Scope and Segmentation
 - 1.4.1. Key Market Segments
 - 1.4.2. Key Countries and Regions
 - 1.4.3. Top Companies in the Respiratory Syncytial Virus Vaccines Industry
- 1.5. Macroeconomic and Demographic Outlook
 - 1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
 - 1.5.2. Population Forecast by Country, 2010- 2040
 - 1.5.3. Inflation Trends in Leading Countries
- 1.6. Impact of Trade Policies, Regulations, and Sustainability
 - 1.6.1. Trade tariffs and localization requirements
 - 1.6.2. ESG and sustainability pressures
 - 1.6.3. Compliance-driven structural changes in the value chain

CHAPTER 2- RESEARCH METHODOLOGY

- 2.1. Report Coverage
- 2.2. Secondary Research
- 2.3. Primary Research
- 2.4. Data Triangulation
- 2.5. Market Modeling and Forecasting

CHAPTER 3- GLOBAL RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034

- 3.1. An Introduction to Global Respiratory Syncytial Virus Vaccines Markets in 2026
- 3.2. Global Historic and Forecast Respiratory Syncytial Virus Vaccines Market Size Outlook, USD Million, 2021- 2034
- 3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
- 3.4. Market Dynamics

3.4.1. Key Respiratory Syncytial Virus Vaccines Market Driving Forces and Their Impact on Market Outlook

3.4.2. Short and Long-Term Trends and Insights Shaping the Future

3.4.3. Potential Respiratory Syncytial Virus Vaccines Market Opportunities for Industry Stakeholders

3.4.4. Potential Challenges across Respiratory Syncytial Virus Vaccines Value Chain

CHAPTER 4- RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT

4.1. Porter's Five Forces Analysis

4.1.1. Bargaining Power of Buyers

4.1.2. Bargaining Power of Suppliers

4.1.3. Threat of Substitutes

4.1.4. Threat of New Entrants

4.1.5. Intensity of Competitive Rivalry

4.1.6. Market Attractiveness Analysis by Segment

4.1.7. Market Attractiveness Analysis by Region

4.2. Competitive Landscape

4.2.1 Market Share Analysis of Leading Respiratory Syncytial Virus Vaccines Companies

4.2.2 Recent Strategic Developments

4.2.3 Mergers, Acquisitions, and Partnerships

4.2.4 Product Launches and Innovation Trends

4.2.5 Key Success Factors

4.3. Value Chain Analysis

4.3.1. Key Value Chain Segments

4.3.2. Dominant players by value-chain stage

4.4. SWOT Analysis

4.4.1. Key Strengths and Opportunities

4.4.2. Major Weaknesses and Threats

4.5 Technology Roadmap

4.6 Regulatory and Reimbursement Landscape

CHAPTER 5- RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET OUTLOOK BY SEGMENTS

5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034

Respiratory Syncytial Virus Vaccines Market Size, Share and Growth Outlook 2026: By Product Type, By Immunizat...

5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034

5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034

By Product Type

Elderly RSV Vaccines

Pediatric RSV Vaccines

Maternal RSV Vaccines

By Immunization Approach

Active Immunization

Passive Immunization

By Technology Platform

Recombinant / Subunit Protein-based Vaccines

mRNA-based Vaccines

Viral Vector-based Vaccines

Live Attenuated Vaccines

By Route of Administration

Intramuscular Injection

Intranasal / Mucosal Delivery

By End User

Hospitals and Specialized Clinics

Retail Pharmacies and Drugstores

Government Procurement / Public Health Vaccination Centers

CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK

6.1. Base Case Scenario

6.1.1. Definitions and Insights

6.1.2. Market Size Outlook to 2034

6.2. Low Growth Case Scenario

6.2.1. Definitions and Insights

6.2.2. Market Size Outlook to 2034

6.3. High Growth Case Scenario

6.3.1. Definitions and Insights

6.3.2. Market Size Outlook to 2034

CHAPTER 7- NORTH AMERICA RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE ANALYSIS AND OUTLOOK

7.1. North America Respiratory Syncytial Virus Vaccines Market Overview, 2026

7.2. Leading Companies Operating in North America

7.3. Key Industry Statistics, 2026

7.4. North America Respiratory Syncytial Virus Vaccines Market Trends and Growth Opportunities to 2034

7.5. North America Respiratory Syncytial Virus Vaccines Market Size Outlook by Type

7.6. North America Respiratory Syncytial Virus Vaccines Market Size Outlook by Application

7.7. North America Respiratory Syncytial Virus Vaccines Market Size Outlook by Country

7.8. United States

7.8.1. Key Statistics

7.8.2. The US Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

7.8.3. Key Market Drivers and Industry Developments in the US Respiratory Syncytial Virus Vaccines Companies

7.9. Canada

7.9.1. Key Statistics

7.9.2. Canada Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

7.9.3. Key Market Drivers and Industry Developments in Canada Respiratory Syncytial Virus Vaccines Companies

7.10. Mexico

7.10.1. Key Statistics

7.10.2. Mexico Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

7.10.3. Key Market Drivers and Industry Developments in Mexico Respiratory Syncytial Virus Vaccines Companies

CHAPTER 8- EUROPE RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE ANALYSIS AND OUTLOOK

8.1. Europe Respiratory Syncytial Virus Vaccines Market Overview, 2026

8.2. Leading Companies Operating in Europe

8.3. Key Industry Statistics, 2026

8.4. Europe Respiratory Syncytial Virus Vaccines Market Trends and Growth Opportunities to 2034

8.5. Europe Respiratory Syncytial Virus Vaccines Market Size Outlook by Type

8.6. Europe Respiratory Syncytial Virus Vaccines Market Size Outlook by Application

8.7. Europe Respiratory Syncytial Virus Vaccines Market Size Outlook by Country

8.8. Germany

8.8.1. Key Statistics

8.8.2. Germany Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.8.3. Key Market Drivers and Industry Developments in Germany Respiratory

Syncytial Virus Vaccines Companies

8.9. France

8.9.1. Key Statistics

8.9.2. France Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.9.3. Key Market Drivers and Industry Developments in France Respiratory Syncytial Virus Vaccines Companies

8.10. United Kingdom

8.10.1. Key Statistics

8.10.2. United Kingdom Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.10.3. Key Market Drivers and Industry Developments in the UK Respiratory Syncytial Virus Vaccines Companies

8.11. Spain

8.11.1. Key Statistics

8.11.2. Spain Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.11.3. Key Market Drivers and Industry Developments in Spain Respiratory Syncytial Virus Vaccines Companies

8.12. Italy

8.12.1. Key Statistics

8.12.2. Italy Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.12.3. Key Market Drivers and Industry Developments in Italy Respiratory Syncytial Virus Vaccines Companies

8.13. Rest of Europe

8.13.1. Key Statistics

8.13.2. Rest of Europe Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Respiratory Syncytial Virus Vaccines Companies

CHAPTER 9- ASIA PACIFIC RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE ANALYSIS AND OUTLOOK

9.1. Asia Pacific Respiratory Syncytial Virus Vaccines Market Overview, 2026

9.2. Leading Companies Operating in Asia Pacific

9.3. Key Industry Statistics, 2026

9.4. Asia Pacific Respiratory Syncytial Virus Vaccines Market Trends and Growth Opportunities to 2034

9.5. Asia Pacific Respiratory Syncytial Virus Vaccines Market Size Outlook by Type

9.6. Asia Pacific Respiratory Syncytial Virus Vaccines Market Size Outlook by

Application

9.7. Asia Pacific Respiratory Syncytial Virus Vaccines Market Size Outlook by Country

9.8. China

9.8.1. Key Statistics

9.8.2. China Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.8.3. Key Market Drivers and Industry Developments in China Respiratory Syncytial Virus Vaccines Companies

9.9. Japan

9.9.1. Key Statistics

9.9.2. Japan Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.9.3. Key Market Drivers and Industry Developments in Japan Respiratory Syncytial Virus Vaccines Companies

9.10. India

9.10.1. Key Statistics

9.10.2. India Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.10.3. Key Market Drivers and Industry Developments in India Respiratory Syncytial Virus Vaccines Companies

9.11. South Korea

9.11.1. Key Statistics

9.11.2. South Korea Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.11.3. Key Market Drivers and Industry Developments in South Korea Respiratory Syncytial Virus Vaccines Companies

9.12. Australia

9.12.1. Key Statistics

9.12.2. Australia Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.12.3. Key Market Drivers and Industry Developments in Australia Respiratory Syncytial Virus Vaccines Companies

9.13. Southeast Asia

9.13.1. Key Statistics

9.13.2. Southeast Asia Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034

9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Respiratory Syncytial Virus Vaccines Companies

CHAPTER 10- SOUTH AND CENTRAL AMERICA RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE ANALYSIS AND OUTLOOK

- 10.1. South and Central America Respiratory Syncytial Virus Vaccines Market Overview, 2026
- 10.2. Leading Companies Operating in South and Central America
- 10.3. Key Industry Statistics, 2026
- 10.4. South and Central America Respiratory Syncytial Virus Vaccines Market Trends and Growth Opportunities to 2034
- 10.5. South and Central America Respiratory Syncytial Virus Vaccines Market Size Outlook by Type
- 10.6. South and Central America Respiratory Syncytial Virus Vaccines Market Size Outlook by Application
- 10.7. South and Central America Respiratory Syncytial Virus Vaccines Market Size Outlook by Country
- 10.8. Brazil
 - 10.8.1. Key Statistics
 - 10.8.2. Brazil Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034
 - 10.8.3. Key Market Drivers and Industry Developments in Brazil Respiratory Syncytial Virus Vaccines Companies
- 10.9. Argentina
 - 10.9.1. Key Statistics
 - 10.9.2. Argentina Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034
 - 10.9.3. Key Market Drivers and Industry Developments in Argentina Respiratory Syncytial Virus Vaccines Companies
- 10.10. Rest of Latin America
 - 10.10.1. Key Statistics
 - 10.10.2. Rest of Latin America Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034
 - 10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Respiratory Syncytial Virus Vaccines Companies

CHAPTER 11- MIDDLE EAST AND AFRICA RESPIRATORY SYNCYTIAL VIRUS VACCINES MARKET SIZE ANALYSIS AND OUTLOOK

- 11.1. Middle East and Africa Respiratory Syncytial Virus Vaccines Market Overview, 2026
- 11.2. Leading Companies Operating in Middle East and Africa
- 11.3. Key Industry Statistics, 2026
- 11.4. Middle East and Africa Respiratory Syncytial Virus Vaccines Market Trends and Growth Opportunities to 2034

- 11.5. Middle East and Africa Respiratory Syncytial Virus Vaccines Market Size Outlook by Type
- 11.6. Middle East and Africa Respiratory Syncytial Virus Vaccines Market Size Outlook by Application
- 11.7. Middle East and Africa Respiratory Syncytial Virus Vaccines Market Size Outlook by Country
- 11.8. Saudi Arabia
 - 11.8.1. Key Statistics
 - 11.8.2. Saudi Arabia Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021-2034
 - 11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Respiratory Syncytial Virus Vaccines Companies
- 11.9. United Arab Emirates
 - 11.9.1. Key Statistics
 - 11.9.2. The UAE Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021-2034
 - 11.9.3. Key Market Drivers and Industry Developments in the UAE Respiratory Syncytial Virus Vaccines Companies
- 11.10. Africa
 - 11.10.1. Key Statistics
 - 11.10.2. Africa Respiratory Syncytial Virus Vaccines Market Size Outlook, 2021- 2034
 - 11.10.3. Key Market Drivers and Industry Developments in Africa Respiratory Syncytial Virus Vaccines Companies

CHAPTER 12- COMPANY PROFILES

- 12.1. Top Companies in Respiratory Syncytial Virus Vaccines Industry
 - GSK plc
 - Pfizer Inc.
 - Moderna, Inc.
 - Sanofi S.A.
 - AstraZeneca plc
 - Merck & Co., Inc.
 - Bavarian Nordic
 - Icosavax, Inc.
 - Meissa Vaccines, Inc.
 - Codagenix, Inc.
- 12.2. Business Description
- 12.3. SWOT Profiles

12.4. Products and Services

CHAPTER 13- APPENDIX

Glossary of Terms

Research Methodology & Data Sources

Conclusion & Strategic Recommendations

I would like to order

Product name: Respiratory Syncytial Virus Vaccines Market Size, Share and Growth Outlook 2026: By Product Type, By Immunization Approach, By Technology Platform, By Route of Administration, By End User, Companies to 2034

Product link: <https://marketpublishers.com/r/RF4926DCD11EEN.html>

Price: US\$ 3,482.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RF4926DCD11EEN.html>